tetano
Editor, Senior Moderator
Arch Virol
. 2022 Sep 9.
doi: 10.1007/s00705-022-05562-z. Online ahead of print.
Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice
Zhuo-Xin Li[SUP] 1 2 [/SUP], Sheng Feng[SUP] 2 [/SUP], He Zhang[SUP] 2 [/SUP], Xin-Yu Zhuang[SUP] 2 [/SUP], Chao Shang[SUP] 2 [/SUP], Shi-Yu Sun[SUP] 2 [/SUP], Ji-Cheng Han[SUP] 3 [/SUP], Yu-Biao Xie[SUP] 2 [/SUP], Jin-Yong Zhang[SUP] 1 2 [/SUP], Wei Wang[SUP] 2 [/SUP], Cheng-Hui Li[SUP] 2 [/SUP], Guan-Yu Zhao[SUP] 2 [/SUP], Peng-Fei Hao[SUP] 2 [/SUP], Jun-Xian Ma[SUP] 2 [/SUP], Yan Gao[SUP] 2 [/SUP], Jia-Qing Zeng[SUP] 2 [/SUP], Ming-Yao Tian[SUP] 2 [/SUP], Zhuo Ha[SUP] 4 [/SUP], Hui-Jun Lu[SUP] 5 6 [/SUP], Ning-Yi Jin[SUP] 7 8 9 [/SUP]
Affiliations
Abstract
The wide spread of coronavirus disease 2019 (COVID-19) has significantly threatened public health. Human herd immunity induced by vaccination is essential to fight the epidemic. Therefore, highly immunogenic and safe vaccines are necessary to control SARS-CoV-2, whose S protein is the antigenic determinant responsible for eliciting antibodies that prevent viral entry and fusion. In this study, we developed a SARS-CoV-2 DNA vaccine expressing the S protein, named pVAX-S-OP, which was optimized according to the human-origin codon preference and using polyinosinic-polycytidylic acid as an adjuvant. pVAX-S-OP induced specific antibodies and neutralizing antibodies in BALB/c and hACE2 transgenic mice. Furthermore, we observed 1.43-fold higher antibody titers in mice receiving pVAX-S-OP plus adjuvant than in those receiving pVAX-S-OP alone. Interferon gamma production in the pVAX-S-OP-immunized group was 1.58 times (CD3[SUP]+[/SUP]CD4[SUP]+[/SUP]IFN-gamma[SUP]+[/SUP]) and 2.29 times (CD3[SUP]+[/SUP]CD8[SUP]+[/SUP]IFN-gamma[SUP]+[/SUP]) lower than that in the pVAX-S-OP plus adjuvant group but higher than that in the control group. The pVAX-S-OP vaccine was also observed to stimulate a Th1-type immune response. When, hACE2 transgenic mice were challenged with SARS-CoV-2, qPCR detection of N and E genes showed that the viral RNA loads in pVAX-S-OP-immunized mice lung tissues were 10[SUP]4[/SUP] times and 10[SUP]6[/SUP] times lower than those of the PBS control group, which shows that the vaccine could reduce the amount of live virus in the lungs of hACE2 mice. In addition, pathological sections showed less lung damage in the pVAX-S-OP-immunized group. Taken together, our results demonstrated that pVAX-S-OP has significant immunogenicity, which provides support for developing SARS-CoV-2 DNA candidate vaccines.
. 2022 Sep 9.
doi: 10.1007/s00705-022-05562-z. Online ahead of print.
Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice
Zhuo-Xin Li[SUP] 1 2 [/SUP], Sheng Feng[SUP] 2 [/SUP], He Zhang[SUP] 2 [/SUP], Xin-Yu Zhuang[SUP] 2 [/SUP], Chao Shang[SUP] 2 [/SUP], Shi-Yu Sun[SUP] 2 [/SUP], Ji-Cheng Han[SUP] 3 [/SUP], Yu-Biao Xie[SUP] 2 [/SUP], Jin-Yong Zhang[SUP] 1 2 [/SUP], Wei Wang[SUP] 2 [/SUP], Cheng-Hui Li[SUP] 2 [/SUP], Guan-Yu Zhao[SUP] 2 [/SUP], Peng-Fei Hao[SUP] 2 [/SUP], Jun-Xian Ma[SUP] 2 [/SUP], Yan Gao[SUP] 2 [/SUP], Jia-Qing Zeng[SUP] 2 [/SUP], Ming-Yao Tian[SUP] 2 [/SUP], Zhuo Ha[SUP] 4 [/SUP], Hui-Jun Lu[SUP] 5 6 [/SUP], Ning-Yi Jin[SUP] 7 8 9 [/SUP]
Affiliations
- PMID: 36083350
- DOI: 10.1007/s00705-022-05562-z
Abstract
The wide spread of coronavirus disease 2019 (COVID-19) has significantly threatened public health. Human herd immunity induced by vaccination is essential to fight the epidemic. Therefore, highly immunogenic and safe vaccines are necessary to control SARS-CoV-2, whose S protein is the antigenic determinant responsible for eliciting antibodies that prevent viral entry and fusion. In this study, we developed a SARS-CoV-2 DNA vaccine expressing the S protein, named pVAX-S-OP, which was optimized according to the human-origin codon preference and using polyinosinic-polycytidylic acid as an adjuvant. pVAX-S-OP induced specific antibodies and neutralizing antibodies in BALB/c and hACE2 transgenic mice. Furthermore, we observed 1.43-fold higher antibody titers in mice receiving pVAX-S-OP plus adjuvant than in those receiving pVAX-S-OP alone. Interferon gamma production in the pVAX-S-OP-immunized group was 1.58 times (CD3[SUP]+[/SUP]CD4[SUP]+[/SUP]IFN-gamma[SUP]+[/SUP]) and 2.29 times (CD3[SUP]+[/SUP]CD8[SUP]+[/SUP]IFN-gamma[SUP]+[/SUP]) lower than that in the pVAX-S-OP plus adjuvant group but higher than that in the control group. The pVAX-S-OP vaccine was also observed to stimulate a Th1-type immune response. When, hACE2 transgenic mice were challenged with SARS-CoV-2, qPCR detection of N and E genes showed that the viral RNA loads in pVAX-S-OP-immunized mice lung tissues were 10[SUP]4[/SUP] times and 10[SUP]6[/SUP] times lower than those of the PBS control group, which shows that the vaccine could reduce the amount of live virus in the lungs of hACE2 mice. In addition, pathological sections showed less lung damage in the pVAX-S-OP-immunized group. Taken together, our results demonstrated that pVAX-S-OP has significant immunogenicity, which provides support for developing SARS-CoV-2 DNA candidate vaccines.